Ian Tomlinson, senior vice-president and head of biopharmaceuticals R&D at GlaxoSmithKline, has been appointed to the Bioindustry Association’s board of directors.
Other new members are Janis Clayton, vice-president of Shire Human Genetic Therapies; Keith Martin, chief executive of biotechnology company Apitope; and Diana Sternfeld a partner at intellectual property firm Rouse Legal. They will take up their appointments from 1 January.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.